is semaglutide patented Off-patent in 2026: the next revolution in anti-obesity medications Massive Rs 50,000 Cr Opportunity

Safety Considerations and Regulatory Warnings Melanotan II remains unapproved, and products sold through unregulated channels may have uncertain identity, content, purity, sterility, and storage history

Also, given the observational nature of the study, we could expect the presence of indication bias, a type of confounding bias that occurs when a symptom or sign of disease is judged as an indication for a given therapy, and is therefore associated both with the use of a drug and with a higher probability of an outcome related to the disease for which the agent is indicated [37]

-:

Discussion Clinical trials have indicated that leptin administration failed as an efficient therapeutical approach to treat obesity 24,25,26 , although it attenuates the neuroendocrine and metabolic changes induced by weight loss 1,2,3,4,5